BSE · 540737
Shree Ganesh Remedies Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹33 Cr with net profit ₹6 Cr — a 18.89% net margin, versus 14.68% the period before.
Shareholding
As of 2026-06-30
- Promoter72.84%
- Public26.64%
- DII0.52%
7,822 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #54 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,732 Cr | 38.44 | 5.72 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,036 Cr | 214.48 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,761 Cr | 70.18 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,115 Cr | 192.98 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,159 Cr | 344.27 | 18.13 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,303 Cr | 430.87 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,092 Cr | 99.97 | 2.43 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,926 Cr | 546.08 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,853 Cr | 287.05 | 4.91 | 16.66% | 15.65% |
| Shree Ganesh Remedies Limited(this company) | ₹801 Cr | 45.12 | 4.92 | 10.9% | 16.26% |
AI analysis
AI-generated · google/gemini-2.5-flashShree Ganesh Remedies Limited is listed on the Indian markets with a market capitalization of Rs 828 Cr. The company reported revenue of Rs 112.33 Cr and a profit margin of 16.26%. Its earnings per share (EPS) stands at Rs 13.83. The return on equity (ROE) is 10.9% and return on capital employed (ROCE) is 14.23%. The debt-to-equity ratio is 0.28.
Positives
- +Promoter holding is high at 72.8369% as of March 31, 2026.
- +The company has a positive profit margin of 16.26%.
- +Debt-to-equity ratio is low at 0.28.
- +Promoter pledge is 0%, indicating no shares are pledged.
Negatives
- −The company has not reported a dividend yield, which is 0%.
- −No annual revenue growth figure is provided in the data.
- −Foreign institutional investor (FII) holding is 0% as of March 31, 2026.
- −Quarterly net profit in December 2025 was Rs 3.09 Cr, a decrease from Rs 4.96 Cr in September 2025.
- −Quarterly revenue in December 2025 was Rs 21.11 Cr, a decrease from Rs 30.32 Cr in September 2025.
Financial Performance
For the fiscal year ending March 2025, Shree Ganesh Remedies Limited reported a revenue of Rs 112.326 Cr and a net profit of Rs 23.0684 Cr. Quarterly revenue for March 2026 was Rs 33.2 Cr, with a net profit of Rs 6.27 Cr. This follows a revenue of Rs 21.11 Cr and net profit of Rs 3.09 Cr in December 2025.
Profitability & Returns
The company’s profit margin for the latest period is 16.26%. Return on equity (ROE) is reported at 10.9%, while return on capital employed (ROCE) is 14.23%. Earnings per share (EPS) is Rs 13.83. The company does not currently offer a dividend, with a dividend yield of 0%.
Balance Sheet
Shree Ganesh Remedies Limited maintains a debt-to-equity ratio of 0.28, indicating controlled leverage. The book value per share is Rs 126.95. The company's EPS for March 2025 was Rs 17.96. No further details on specific asset or liability breakdown are available from the provided data.
Ownership & Pledges
As of March 31, 2026, promoter holding in Shree Ganesh Remedies Limited stands at 72.8369%. Public shareholding is 27.1619%. There are no shares pledged by the promoters, with promoter pledge reported at 0%.
Regulatory & Surveillance
No information regarding any surveillance measures or specific regulatory actions pertaining to Shree Ganesh Remedies Limited is available in the provided data.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Shree Ganesh Remedies Limitedshare price & fundamentals